 |
 |
 |
|  |
|
|
|
| |
|
 |
|
|
|
 |
 |
   |
|
December 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read December 10, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read December 6, 2018 - Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Read December 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Read December 6, 2018 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Read December 3, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read November 7, 2018 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference Read November 1, 2018 - Puma Biotechnology Reports Third Quarter 2018 Financial Results Read October 18, 2018 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read October 10, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read October 2, 2018 - Puma Biotechnology’s Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China Read September 20, 2018 - Puma Biotechnology to Present at Cantor Global Healthcare Conference Read September 6, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read September 4, 2018 - European Commission Grants Marketing Authorisation for Puma Biotechnology’s NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer Read August 9, 2018 - Puma Biotechnology Reports Second Quarter 2018 Financial Results Read July 31, 2018 - Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada Read July 26, 2018 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read July 17, 2018 - Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial) Read June 29, 2018 - Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX® for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Read June 26, 2018 - Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Read June 2, 2018 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting Read May 30, 2018 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference Read May 9, 2018 - Puma Biotechnology Reports First Quarter 2018 Financial Results Read May 8, 2018 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018 Read April 25, 2018 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read April 3, 2018 - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America Read April 2, 2018 - NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination with Capecitabine or Paclitaxel as Treatment Options for Patients with Breast Cancer Brain Metastases Read March 6, 2018 - Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference Read March 1, 2018 - Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results Read February 23, 2018 - Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Read February 15, 2018 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results Read February 7, 2018 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference Read February 1, 2018 - Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China Read January 31, 2018 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers - Data published online today in Nature - Read January 30, 2018 - Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel Read January 29, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read January 23, 2018 - Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Read |
|
November 14, 2018 - Credit Suisse 27th Annual Healthcare Conference More November 1, 2018 - Puma Biotechnology 3Q-2018 Financial Results Conference Call More October 1, 2018 - Cantor Global Healthcare Conference More September 12, 2018 - Morgan Stanley 16th Annual Global Healthcare Conference More September 6, 2018 - Citi’s 13th Annual Biotech Conference More August 9, 2018 - Puma Biotechnology 2Q-2018 Financial Results Conference Call More June 7, 2018 - Jefferies Global Healthcare Conference More June 1-5, 2018 - ASCO 2018 Annual Meeting More May 16, 2018 - Bank of America Merrill Lynch Health Care Conference 2018 More May 9, 2018 - Puma Biotechnology 1Q-2018 Financial Results Conference Call More March 13, 2018 - Cowen and Company 38th Annual Health Care Conference More March 1, 2018 - Puma Biotechnology 4Q-2017 Financial Results Conference Call More February 14, 2018 - LEERINK Partners 7th Annual Global Healthcare Conference More December 5 – 9, 2017 - San Antonio Breast Cancer Symposium More November 15, 2017 - Stifel 2017 Healthcare Conference More November 9, 2017 - Puma Biotechnology 3Q-2017 Financial Results More November 7, 2017 - Credit Suisse Healthcare Conference More |
    Annual Report Archives  Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150 Los Angeles, CA 90024 424-248-6500 Main 424-248-6501 Fax Medical Inquiries: 1-844-MED-PUMA (1-844-633-7862), or medinfo@pumabiotechnology.com Business Development: info@pumabiotechnology.com Investor Relations: ir@pumabiotechnology.com |
|
 © 2018 Puma Biotechnology, Inc. | Privacy Policy | Legal Notice | Site Map |